Close Menu

This article has been updated to include a comment from a Helix customer and to correct that it is whole-exome sequencing, not Helix's Exome+ assay, that was authorized by the FDA.

NEW YORK – Helix said on Monday that it has received de novo authorization from the US Food and Drug Administration for its whole-exome sequencing platform, as well as 510(k) clearance for a direct-to-consumer genetic risk test for late-onset Alzheimer's disease.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.